Log in

Cesca Therapeutics Stock Price, Forecast & Analysis (NASDAQ:KOOL)

$5.14
+0.35 (+7.31 %)
(As of 10/31/2019)
Today's Range
$4.80
Now: $5.14
$5.20
50-Day Range
$4.27
MA: $5.59
$6.80
52-Week Range
$2.10
Now: $5.14
$7.00
Volume84,200 shs
Average Volume96,680 shs
Market Capitalization$12.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. Read More…

Industry, Sector and Symbol

Industry Laboratory apparatus & furniture
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KOOL
CUSIPN/A
Phone916-858-5100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.67 million
Book Value$3.11 per share

Profitability

Net Income$-39,720,000.00

Miscellaneous

Employees53
Market Cap$12.44 million
Next Earnings DateN/A
OptionableNot Optionable

Receive KOOL News and Ratings via Email

Sign-up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter.


Cesca Therapeutics (NASDAQ:KOOL) Frequently Asked Questions

What is Cesca Therapeutics' stock symbol?

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

How were Cesca Therapeutics' earnings last quarter?

Cesca Therapeutics Inc (NASDAQ:KOOL) issued its earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative return on equity of 77.30% and a negative net margin of 98.84%. View Cesca Therapeutics' Earnings History.

What price target have analysts set for KOOL?

1 analysts have issued twelve-month price objectives for Cesca Therapeutics' shares. Their forecasts range from $7.50 to $7.50. On average, they anticipate Cesca Therapeutics' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price. View Analyst Price Targets for Cesca Therapeutics.

What is the consensus analysts' recommendation for Cesca Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cesca Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cesca Therapeutics.

Has Cesca Therapeutics been receiving favorable news coverage?

News headlines about KOOL stock have trended somewhat positive on Sunday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cesca Therapeutics earned a news impact score of 2.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Cesca Therapeutics.

Are investors shorting Cesca Therapeutics?

Cesca Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totalling 208,500 shares, an increase of 14.1% from the September 15th total of 182,700 shares. Based on an average daily trading volume, of 202,800 shares, the short-interest ratio is currently 1.0 days. Currently, 12.1% of the company's shares are short sold. View Cesca Therapeutics' Current Options Chain.

Who are some of Cesca Therapeutics' key competitors?

What other stocks do shareholders of Cesca Therapeutics own?

Who are Cesca Therapeutics' key executives?

Cesca Therapeutics' management team includes the folowing people:
  • Dr. Xiaochun Xu M.B.A., Ph.D., Chairman, CEO & Pres (Age 48)
  • Mr. Jeff Cauble, Principal Financial & Accounting Officer (Age 46)
  • Mr. James Xu J.D., L.L.M., M.B.A., Director, Gen. Counsel, Sr. VP of Legal Affairs & Cybersecurity and Corp. Sec. (Age 48)
  • Mr. Philip H. Coelho, Chief Technology Officer (Age 75)
  • Ms. Haihong Zhu, Pres of ThermoGenesis

How do I buy shares of Cesca Therapeutics?

Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cesca Therapeutics' stock price today?

One share of KOOL stock can currently be purchased for approximately $5.14.

How big of a company is Cesca Therapeutics?

Cesca Therapeutics has a market capitalization of $12.44 million and generates $9.67 million in revenue each year. The biotechnology company earns $-39,720,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. Cesca Therapeutics employs 53 workers across the globe.View Additional Information About Cesca Therapeutics.

What is Cesca Therapeutics' official website?

The official website for Cesca Therapeutics is http://www.cescatherapeutics.com/.

How can I contact Cesca Therapeutics?

Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]


MarketBeat Community Rating for Cesca Therapeutics (NASDAQ KOOL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  213 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote "Outperform" if you believe KOOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel